Autolus Therapeutics (AUTL) Misses Q2 EPS by 4c

Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.46), $0.04 worse than the analyst estimate of ($0.42).

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.

You May Also Be Interested In

• Goldman: 'Our top picks include XYZ, KLAR, AFRM, and CHYM'
• Simply Good Foods posts Q3 loss, cuts fiscal 2026 outlook
• Chubb Corporation (CB) PT Raised to $337 at Cantor Fitzgerald: 'Remains Well-Positioned'